Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.pdindia.com | |
Market Cap | 12.52 Cr. | |
Enterprise Value(EV) | 118.76 Cr. | 2022-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -25.61 | Trailing Twelve Months Ending 2022-03 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-03 |
Industry PE | 32.78 | Trailing Twelve Months Ending 2022-03 |
Book Value / Share | -278.81 | Trailing Twelve Months Ending 2022-03 |
Price to Book Value | -0.02 | Calculated using Price: 4.20 |
Dividend Yield | 0.00 | Period Ending 2021-03 |
No. of Shares Subscribed | 2.98 Cr. | 29,816,300 Shares |
FaceValue | 10 | |
Company Profile | ||
Established in the year 1983, Parenteral Drugs has dedicated itself to the manufacturing of the best quality vital life saving drug at the lowest possible cost. Over the years, its path breaking innovation has led not only to lower costs but better quality as well because PDPL firmly believes that better quality dose not necessarily mean higher price, it can also be achieved by indigenous techniques and innovative technologies. |
1 Day |
|
|
1 Week |
|
|
1 Month |
|
+3.70% |
3 Month |
|
-12.50% |
6 Month |
|
+9.09% |
1 Year |
|
+6.33% |
2 Year |
|
+61.54% |
5 Year |
|
-79.56% |
10 Year |
|
-95.88% |
9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | -44.85 | -23.61 | -46.67 | -152.43 | ||||||
Return on Capital Employed (%) | -5.15 | 1.90 | -2.29 | -8.13 | -6.91 | -5.55 | -35.07 | -52.31 | ||
Return on Assets (%) | -12.80 | -5.44 | -8.41 | -12.60 | -12.16 | -13.17 | -23.45 | -26.72 | -29.65 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
Shh. Funds | 246 | 202 | 127 | 325 | -17 | -136 | -447 | -561 | -683 | -824 | |
Non Curr. Liab. | 427 | 456 | 427 | 440 | 462 | 370 | 4 | -26 | -59 | -91 | |
Curr. Liab. | 162 | 166 | 230 | 300 | 428 | 593 | 878 | 1,006 | 1,144 | 1,201 | |
Minority Int. | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
Equity & Liab. | 835 | 825 | 785 | 1,066 | 872 | 827 | 435 | 419 | 402 | 286 | |
Non Curr. Assets | 629 | 619 | 549 | 902 | 750 | 727 | 368 | 351 | 334 | 219 | |
Curr. Assets | 192 | 200 | 235 | 163 | 122 | 99 | 67 | 67 | 68 | 67 | |
Misc. Exp. not W/O | 14 | 5 | 1 | 1 | |||||||
Total Assets | 835 | 825 | 785 | 1,066 | 872 | 827 | 435 | 419 | 402 | 286 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
Net Sales | 327 | 274 | 263 | 260 | 230 | 224 | 32 | 32 | 12 | 9 | |
Other Income | 0 | 61 | 1 | 2 | 6 | 2 | 1 | 0 | 0 | 0 | |
Total Income | 328 | 334 | 264 | 262 | 236 | 226 | 33 | 32 | 12 | 9 | |
Total Expenditure | -341 | -350 | -248 | -296 | -252 | -225 | -50 | -47 | -24 | -24 | |
PBIDT | -14 | -15 | 15 | -34 | -17 | 0 | -16 | -14 | -12 | -16 | |
Interest | -56 | -60 | -70 | -70 | -86 | -98 | -96 | -110 | -125 | -106 | |
Depreciation | -23 | -19 | -31 | -23 | -25 | -24 | -69 | -17 | -17 | -40 | |
Taxation | -15 | 1 | 19 | 10 | 10 | 10 | 33 | 28 | 33 | 33 | |
Exceptional Items | 47 | 0 | -1 | 0 | 52 | ||||||
PAT | -108 | -45 | -68 | -117 | -118 | -112 | -148 | -114 | -122 | -76 | |
Minority Interest | |||||||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | -108 | -45 | -68 | -117 | -118 | -112 | -148 | -114 | -122 | -76 | |
Adjusted EPS | -42 | -15 | -23 | -39 | -40 | -38 | -50 | -38 | -41 | -26 |
Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | 20 | -168 | -60 | 2 | 58 | 134 | 167 | 477 | 112 | 125 | |
Cash Fr. Inv. | -147 | -18 | 33 | 3 | -110 | -1 | -1 | 97 | 0 | 0 | |
Cash Fr. Finan. | 133 | 182 | 25 | -10 | 54 | -134 | -167 | -574 | -112 | -125 | |
Net Change | 5 | -3 | -2 | -5 | 1 | 0 | 0 | 0 | 0 | 0 | |
Cash & Cash Eqvt | 13 | 11 | 8 | 3 | 5 | 0 | 0 | 0 | 0 | 0 |
Thu, 25 Aug 2022
Communication to shareholders as per Reg 30
|
|
Wed, 24 Aug 2022
Communication to shareholders as per Reg 30
|
|
Thu, 11 Aug 2022
Resignation
|
Mon, 30 Jan 2023 |
|
|
|
|
|